Optimizing Treatment for Patients with CLL
Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in Western countries, with an age-adjusted incidence of 4.6 per 100,000 individuals per year. As small lymphocytic lymphoma (SLL) refers to the same malignant process with primary nodal involvement rather than blood, these are generally managed as a single condition (CLL/SLL). The selection of therapies for patients with relapsed/refractory CLL/SLL requires consideration of several factors including previous therapies, disease characteristics, and patient-specific factors such as co-morbidities and concurrent medications. Given the recency of new research into these targeted treatments and new approvals, clinicians lack background knowledge of the most current evidence and guideline recommendations in the treatment of CLL/SLL. Even within national guidelines, specific recommendations for initial treatment choice and sequencing are not directed. This collaborative social learning platform establishes a network of providers who can support each other locally, as well as those from different communities, with the goal of learning and sharing best practices that will improve outcomes for patients with relapsed/refractory chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL).<br> <img src="https://s3.amazonaws.com/media.gathered.com/author/medicallogix/jhu-logo.jpg" width="200" alt="John Hopkins Medicine Logo" title="John Hopkins Medicine Logo">
Practical Strategies for Antidepressant Selection, Dosing and Augmentation in Major Depressive Disorder
In the United States (U.S.), major depressive disorder (MDD) is a prevalent and debilitating illness with a high burden of disease. Effective management of depression is therefore critical, yet achieving and sustaining remission remains challenging in practice. While many patients respond to initial antidepressant therapy, only a minority achieve full remission of symptoms with a first-line treatment. Clinical trials and meta-analyses show that remission rates with a first SSRI/SNRI trial are only on the order of 30–45%, and response (≥50% symptom improvement) occurs in roughly 40–60% of patients.8 Therefore, modern depression management must aim not just for symptom relief, but for full functional recovery. This educational initiative establishes impactful small group interactions among highly qualified psychiatric care providers that will, through a variety of collaborative educational experiences, help them optimize the care of their patients with MDD.<br> <img src="https://s3.amazonaws.com/media.gathered.com/author/medicallogix/jhu-logo.jpg" width="200" alt="John Hopkins Medicine Logo" title="John Hopkins Medicine Logo">
Precision in practice for Advanced/Recurrent Endometrial Cancer
Endometrial cancer is among the few cancers increasing in incidence and mortality in the United States. In its early stages, endometrial carcinoma has a five-year relative survival rate of 96%, but it decreases to 18% for those with metastases. Surprisingly, mortality has been increasing faster than incidence. This is attributed to increasing rates of advanced cancers, higher-risk histologies, and older age of first diagnosis. Yet, there have also been increases in diagnoses in women aged less than 50 years, based on Surveillance, Epidemiology, and End Results (SEER) program data. While the incidence and mortality has been increasing across all racial groups, the rate of increase for Black women has been the steepest. Adjusting for the higher rate of hysterectomy in Black women compared with White women, the differing rates of this cancer in these groups exemplify this racial disparity. These statistics demonstrate the need for new therapeutics and subsequent education on their use in this field. To improve clinical outcomes, clinicians treating patients for advanced/recurrent endometrial cancer need to understand biomarker testing and molecular classification of disease, newest guidelines on management, and the evidence underlying these recommendations. Along with this, clinicians must be aware of the most effective ways to manage possible adverse events. To these ends, this educational initiative will allow clinicians managing patients with advanced/recurrent endometrial cancer to learn and discuss the crucial points in diagnosing and managing these patients to best increase long-term survival.<br> <img src="https://s3.amazonaws.com/media.gathered.com/author/medicallogix/montefiore-einstein.png" width="230" alt="Montefiore Einstein Logo" title="Montefiore Einstein Logo">
Treatment of Early-Stage Non-Small Cell Lung Cancer
Immunotherapy, which has demonstrated benefits in advanced and metastatic settings, is moving into early non-small cell lung cancer treatment, expanding options for patients with resected or resectable early-stage non-small cell lung cancer. This rapid evolution of the early NSCLC treatment landscape, while exciting, has created clinical challenges as health care providers struggle with translating these clinical trial results into real-world clinical practices in the adjuvant and neoadjuvant settings. This educational initiative establishes impactful small group interactions among oncology care providers that will, through a variety of collaborative educational experiences, help them optimize the care of their patients with early-stage NSCLC.<br> <img src="https://s3.amazonaws.com/media.gathered.com/author/medicallogix/jhu-logo.jpg" width="200" alt="John Hopkins Medicine Logo" title="John Hopkins Medicine Logo">
Turning Complexity into Clarity in Advanced Cervical Cancer
The current treatment of advanced, recurrent, and metastatic cervical cancer is difficult, especially as treatment progresses to the second line. Considerations for treatment are nuanced and numerous. Factors include prior treatments, treatment timing, and patient preference. The advent of targeted therapies has brought improved outcomes for those patients whose tumors harbor specific mutations. Still for those who are ineligible for targeted therapies, currently available options are lacking. Agents in the pipeline of development and potential approval offer hope for the treatment of this difficult to manage disease. The goal of this educational curriculum, Turning Complexity into Clarity in Advanced Cervical Cancer, is to establish impactful small group interactions between members of the cervical cancer care team that will, through a variety of collaborative educational experiences, help them in learning and sharing best practices that will improve outcomes for patients with cervical cancer.<br> <img src="https://s3.amazonaws.com/media.gathered.com/author/medicallogix/jhu-logo.jpg" width="200" alt="John Hopkins Medicine Logo" title="John Hopkins Medicine Logo">
Turning Complexity into Clarity in AML
Acute myeloid leukemia (AML) continues to be the most common acute leukemia in adults, with an incidence of 5.5 cases per 100,000 persons annually. As such, more education is needed on key topics including use of induction therapy in the non-elderly population, treating suboptimal response to induction therapy, best practices for measurable (or minimal) residual disease assessment, and proper use of maintenance therapy..The goal of this educational curriculum, Turning Complexity into Clarity in AML, is to establish impactful small group interactions between members of the AML care team that will, through a variety of collaborative educational experiences, help them in learning and sharing best practices that will improve outcomes for patients with AML.<br> <img src="https://s3.amazonaws.com/media.gathered.com/author/medicallogix/montefiore-einstein.png" width="230" alt="Montefiore Einstein Logo" title="Montefiore Einstein Logo">
Turning Complexity into Clarity in Chronic Immune-Mediated Neuropathies
Often seen in Guillain–Barré syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy (MMN), arise as a consequence of immune system involvement and can have myriad health consequences. Both CIDP and MMN are characterized by complex presentations and frequent misdiagnoses. CIDP shows gradual peripheral nerve demyelination, leading to weakness and sensory loss, while MMN presents with asymmetric weakness devoid of sensory complications. With an array of treatment options, managing polyneuropathy in CIDP and MMN can be challenging. This collaborative platform serves as a unifying space for healthcare providers, facilitating the exchange of insights and elevating the standard of care for patients affected by CIDP and MMN. In this learning activity, you will learn how to enhance the lives of CIDP and MMN patients via a program promoting local and cross-community support, driving effective practice-sharing for better outcomes.<br> <img src="https://s3.amazonaws.com/media.gathered.com/author/medicallogix/jhu-logo.jpg" width="200" alt="John Hopkins Medicine Logo" title="John Hopkins Medicine Logo">
Turning Complexity into Clarity in HAE Prophylaxis
Hereditary angioedema (HAE) is a rare but potentially life-threatening disease affecting approximately 1 in 67,000 individuals, with no identified differences in prevalence due to sex or ethnicity. The disease commonly presents with recurrent attacks of swelling in any part of the body. Given the physical and psychosocial impact of HAE on patients and their families, many patients benefit from effective long-term prophylaxis. However, there are numerous clinical gaps impacting the initiation of effective HAE prophylaxis. This collaborative social learning platform aims to help close those gaps by establishing a network of providers who can connect with and support each other with the aim of learning and sharing best practices that will improve outcomes for patients needing long term HAE prophylaxis. By immersing learners in a personalized educational experience, this program explores the management of HAE in a way that is both informative and practical.<br> <img src="https://s3.amazonaws.com/media.gathered.com/author/medicallogix/jhu-logo.jpg" width="200" alt="John Hopkins Medicine Logo" title="John Hopkins Medicine Logo">
Unlocking the Gaps to Improve SMA Outcomes
Spinal muscular atrophy (SMA) can be a debilitating condition causing immobility, respiratory difficulties, and reduced lifespan. But with the advent of new disease-modifying therapies, the prognosis for patients with SMA has been completely altered. These treatments may help patients live longer, creating unique clinical needs. Adults now make up more than a quarter of patients with SMA. However, there are no specific guidelines for the assessment and treatment of adult patients, leading to gaps in their diagnosis and management. Adult care is complex and requires multidisciplinary care. This collaborative CME provides the opportunity to learn and share best practices that will improve outcomes for patients with SMA.<br> <img src="https://s3.amazonaws.com/media.gathered.com/author/medicallogix/jhu-logo.jpg" width="200" alt="John Hopkins Medicine Logo" title="John Hopkins Medicine Logo">
